Anal Cancer
165
33
44
74
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
30 trials with published results (18%)
Research Maturity
74 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.3%
17 terminated out of 165 trials
81.3%
-5.3% vs benchmark
7%
12 trials in Phase 3/4
41%
30 of 74 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 74 completed trials
Clinical Trials (165)
Distance-Based Exercise to Preserve Function and Prevent Disability
DESTINY-PANTUMOUR04
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment
Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Swabs in Screening for HPV (SWISH)
CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers
ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies